Abstracts tagged "drug treatment"

Abstract Number: 2380 • 2014 ACR/ARHP Annual Meeting
Durability of First Biologic Is Not Influenced By Initial/Early DAS28
Gina Rohekar¹, Binu Jacob², Janet E. Pope³ and Claire Bombardier⁴, ¹Rheumatology, St. Joseph's Hospital, London, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Medicine, Western University, London, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: The Ontario Best Practices Research Initiative (OBRI) collects data on RA treatment in a real-world setting. Patients are enrolled and prospectively followed to…
Abstract Number: 1879 • 2014 ACR/ARHP Annual Meeting
The Efficacy of Pregabalin for Treating Fibromyalgia Patients with Moderate or Severe Baseline Widespread Pain
Andrew Clair and Birol Emir, Pfizer Inc, New York, NY
Background/Purpose: Pregabalin has demonstrated efficacy for the treatment of fibromyalgia (FM), but insufficient evidence exists on how the efficacy of pregabalin may differ by baseline…
Abstract Number: 1499 • 2014 ACR/ARHP Annual Meeting
Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor
Candace Graff¹, Annette Schwartz¹, Jeffrey Voss², Neil Wishart³, Lisa Olson¹, Jonathon George³, Deborah Hyland³ and Heidi Camp⁴, ¹AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²Immunology, AbbVie Pharmaceuticals, Worcester, MA, ³Abbvie Pharmaceuticals, worcester, MA, ⁴1101 Oak Street, Abbvie, Winnetka, IL
Background/Purpose Jak kinase blockade can effectively manage rheumatoid arthritis (RA) and in some cases achieve remission. However, first generation Jak inhibitors have not met expectations…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].